A fast track designation by the FDA expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs.
The drug, ELND005, currently being tested in a mid-stage trial, treats neuropsychiatric symptoms such as agitation or aggression in Alzheimer's disease.
Transition Therapeutics said the drug appeared to decrease the emergence and severity of specific neuropsychiatric symptoms in a previous mid-stage study.
About 90 percent of Alzheimer's patients develop neuropsychiatric symptoms and up to 60 percent develop agitation over the course of their disease, the company said.
Ireland-based Elan Corp Plc is Transition's marketing and development partner.
Transition Therapeutics' Toronto-listed shares closed at C$3.15 on Wednesday.
(Reporting by Krithika Krishnamurthy in Bangalore; Editing by Sriraj Kalluvila)
http://agfataju.blog.com/2013/07/17/downloads-sex-in-the-west-village-nyc/
http://alexandriadbaaf.webs.com/apps/blog/show/30534583
http://friendfeed.com/dafciy/76646991/downloads-complete-book-of-arts-crafts-ebook
http://azralaki.edublogs.org/2013/07/17/download-kitty-and-the-silver-bullet/
http://odizoesyi.metroblog.com/download_front_page_2003_for_dummies_for_dummies_computers_e_book
http://uoqlnlifi.blogdetik.com/2013/07/14/download-effective-elementary-social-studies-e-book/
http://curtisbmo.skyrock.com/3174672305-The-Disheveled-Bed-e-book-downloads.html
http://friendfeed.com/ihihf/971f5dd3/downloads-rachael-ray-365-no-repeats-year-of
http://friendfeed.com/ouydh/c6881a5d/case-of-murdered-muckraker-daisy-dalrymple
http://willisutp.skyrock.com/3174672323-Different-boats-read-online.html